By Doug Macron
Alnylam Pharmaceuticals expects to forge new collaborations over 2010, but company officials last week declined to provide specific guidance on its partnering objectives after falling short of previous expectations.
By Doug Macron
Alnylam Pharmaceuticals expects to forge new collaborations over 2010, but company officials last week declined to provide specific guidance on its partnering objectives after falling short of previous expectations.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.